Gene expression markers for colorectal cancer prognosis

Inventors

Watson, Drew • Paik, Soonmyung • Cowens, Wayne • Baker, Joffre B. • Clark, Kim • Hackett, James

Assignees

Genomic Health Inc • NSABP Foundation Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8153380-B2

Patent

Publication Date

2012-04-10

Expiration Date


Abstract

A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Core Innovation

The invention relates to predicting clinical outcome and recurrence in a human subject diagnosed with colorectal cancer following surgical resection. The approach determines a normalized expression level of an RNA transcript of INHBA, or an expression product thereof, in a biological sample comprising cancer cells obtained from the human subject, and compares the normalized INHBA expression level to gene expression data obtained from colorectal cancer reference samples comprising cancer cells derived from patients with colorectal cancer.

For predicting clinical outcome, the reference patients comprise patients with Dukes C (stage III) colorectal cancer, and the normalized INHBA expression level is negatively correlated with an increased likelihood of a positive clinical outcome. For predicting recurrence, the human subject is diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer, and the normalized INHBA expression level is positively correlated with an increased likelihood of recurrence of colorectal cancer.

The clinical outcome can be expressed using Recurrence-Free Interval (RFI), Overall Survival (OS), Disease-Free Survival (DFS), or Distant Recurrence-Free Interval (DRFI). The analysis also includes statistical analyses linking colorectal cancer gene expression to clinical outcomes using proportional hazards modeling, including Cox regression, proportional hazards and non-linear proportional hazards approaches.

Additional gene expression features include nonzero deviation from linear hazard relationships for RFI, significance metrics such as Hazard Ratio (HR)/Likelihood ratio chi-square (LR Chi-Square), degrees of freedom, and P-value results, non-linear proportional hazards using a 2-parameter natural spline, and RFI association that significantly interacts with tumor stage, including an interaction between Dukes B (stage II) and Dukes C (stage III).

Claims Coverage

The document provides two independent claims. The claims cover comparative prediction driven by normalized INHBA RNA expression directionality against colorectal cancer reference gene-expression data.

Negative INHBA-correlated prediction of positive clinical outcome using normalized RNA expression comparison

A method of predicting clinical outcome for a human subject diagnosed with colorectal cancer following surgical resection, comprising determining a normalized expression level of an RNA transcript of INHBA, or an expression product thereof, in a biological sample comprising cancer cells obtained from the human subject, and predicting the likelihood of a positive clinical outcome by comparing the normalized INHBA expression level to gene expression data from colorectal cancer reference samples comprising cancer cells derived from patients with colorectal cancer, where the reference patients comprise patients with Dukes C (stage III) colorectal cancer and where the normalized INHBA expression level is negatively correlated with an increased likelihood of a positive clinical outcome.

Positive INHBA-correlated prediction of recurrence using normalized RNA expression comparison

A method of predicting in a human subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer a likelihood of recurrence of colorectal cancer following surgical resection, comprising determining the normalized expression level of an RNA transcript of INHBA, or an expression product thereof, in a biological sample comprising cancer cells obtained from the human subject, and predicting the likelihood of recurrence by comparing the normalized INHBA expression level to gene expression data obtained from colorectal cancer reference samples comprising cancer cells derived from patients with colorectal cancer, where the reference patients comprise patients with Dukes C (stage III) colorectal cancer and where the normalized INHBA expression level is positively correlated with an increased likelihood of recurrence of colorectal cancer.

Across the claims, the core inventive coverage is comparative prediction using normalized INHBA RNA expression directionality against colorectal cancer reference gene-expression data: negative correlation for predicting positive clinical outcomes in Dukes C (stage III), and positive correlation for predicting recurrence in Dukes B (stage II) or Dukes C (stage III).

Stated Advantages

Predicts the likelihood of a positive clinical outcome for colorectal cancer after surgical resection using normalized INHBA RNA expression.

Predicts the likelihood of recurrence of colorectal cancer after surgical resection using normalized INHBA RNA expression.

Allows clinical outcome characterization using RFI, OS, DFS, or DRFI.

Supports quantitative likelihood scoring and optionally provides a summarized report.

Documented Applications

Predicting clinical outcome and likelihood of a positive clinical outcome for a human subject diagnosed with colorectal cancer following surgical resection, using normalized INHBA RNA transcript expression compared to colorectal cancer reference gene-expression data from Dukes C (stage III) patients.

Predicting likelihood of recurrence of colorectal cancer following surgical resection for a human subject diagnosed with Dukes B (stage II) or Dukes C (stage III), using normalized INHBA RNA transcript expression compared to reference gene-expression data from Dukes C (stage III) patients.

Optionally increasing therapy when the likelihood of recurrence is increased, based on the recurrence prediction.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.